secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001193125-25-001787
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase shareholders approve 5x authorized share increase to 500M and option repricing
--------------------------------------------------------------------------------

- Stockholders approved increase in authorized common shares from 100M to 500M; Certificate of Amendment filed Jan 3, 2025.
- Approved elimination of 66 2/3% supermajority vote requirement for amendments to Article IV.
- Approved 27,453,993 share increase in 2020 Equity Incentive Plan reserve.
- Approved repricing of certain outstanding stock options; all proposals passed with >97% of votes cast.
- Vote results: share increase – 62.5M for, 377K against; no broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525001787/0001193125-25-001787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525001787/d909904d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-001787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer